TABLE 2.
Changes from baseline in metabolic parameters
| Semaglutide 0.4 mg (n = 34) | Placebo (n = 33) | P value | ||
|---|---|---|---|---|
| Mean relative change from baseline in body weight (%) | ||||
| ETD (95% CI) | ||||
| Week 24 | –8.34 | –0.25 | –8.09 (–9.99, –6.20) | ≤ 0.0001 |
| Week 48 | –11.18 | –0.65 | –10.52 (–13.40, –7.65) | ≤ 0.0001 |
| Week 72 | –10.83 | –1.15 | –9.68 (–12.58, –6.77) | ≤ 0.0001 |
| Mean change from baseline in HbA1c (%‐points) – in subjects with T2D | ||||
| n = 28 | n = 21 | ETD (95% CI) | ||
| Week 24 | –1.03 | 0.05 | –1.08 (–1.44, –0.72) | ≤ 0.0001 |
| Week 48 | –1.01 | –0.05 | –0.97 (–1.34, –0.60) | ≤ 0.0001 |
| Week 72 | –1.03 | –0.03 | –1.00 (–1.38, –0.62) | ≤ 0.0001 |
| Mean change from baseline in fasting plasma glucose (mmol/L) – in subjects with T2D | ||||
| n = 27 | n = 21 | ETD (95% CI) | ||
| Week 24 | –1.97 | 0.04 | –2.01 (–3.03, –0.99) | 0.0003 |
| Week 48 | –1.34 | 0.04 | –1.38 (–2.57, –0.19) | 0.0242 |
| Week 72 | –1.74 | –0.28 | –1.47 (–2.70, –0.24) | 0.0208 |
| Mean ratio to baseline in fasting glucagon – in subjects with T2D | ||||
| ETR (95% CI) | ||||
| Week 24 | 0.69 | 1.00 | 0.69 (0.51, 0.92) | 0.0124 |
| Week 48 | 0.78 | 1.07 | 0.73 (0.55, 0.97) | 0.0291 |
| Week 72 | 0.63 | 0.91 | 0.69 (0.51, 0.93) | 0.0169 |
| Mean ratio to baseline in HOMA‐IR – in subjects with T2D | ||||
| ETR (95% CI) | ||||
| Week 24 | 0.91 | 0.92 | 0.99 (0.70, 1.39) | 0.9470 |
| Week 48 | 0.87 | 0.89 | 0.98 (0.67, 1.43) | 0.9065 |
| Week 72 | 0.84 | 0.89 | 0.94 (0.60, 1.48) | 0.7966 |
Abbreviations: CI, confidence interval; ETD, estimated treatment difference; ETR, estimated treatment ratio; HbA1c, glycated haemoglobin; HOMA‐IR, Homeostatic Model Assessment of Insulin Resistance; T2D, type 2 diabetes.